Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA, USA.
The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Expert Opin Biol Ther. 2021 Apr;21(4):465-471. doi: 10.1080/14712598.2021.1834534. Epub 2020 Oct 19.
Once pulmonary disease progresses to end-stage pulmonary disease, treatment options are very limited. An important advance in the field is the development of a bioartificial lung derived from a generic matrix scaffold populated with patients' own cells. Significant progress has already been made in the engineering of bioartificial lungs.
This review explains how previous and current research contributes to the goal of creating a successful bioartificial lung, and the barriers faced in doing so. We will also highlight some of the design considerations being explored to optimize bioartificial lungs and considerations for clinical translation.
While current bioartificial lungs are able to provide short-term gas exchange in large-animal studies, much work is still required to combine the disciplines of cell biology, materials science, and tissue engineering to create such clinically useful and functioning artificial lungs.
一旦肺部疾病发展到终末期肺病,治疗选择就非常有限。该领域的一个重要进展是开发出一种源自通用基质支架的生物人工肺,其中填充有患者自身的细胞。在生物人工肺的工程设计方面已经取得了重大进展。
本综述解释了先前和当前的研究如何有助于实现成功的生物人工肺这一目标,以及在实现这一目标时所面临的障碍。我们还将重点介绍一些正在探索的设计考虑因素,以优化生物人工肺,并考虑临床转化。
虽然目前的生物人工肺能够在大型动物研究中提供短期气体交换,但仍需要做大量工作,将细胞生物学、材料科学和组织工程等学科结合起来,以创造出如此具有临床应用价值和功能的人工肺。